See www.faruqilaw.com. Akero is a clinical stage biopharmaceutical company focused on advancing its lead product candidate efruxifermin ("EFX") to provide a new treatment for patients with ...

Akero Therapeutics and certain executives were hit with a securities class action on April 26 in California Northern District Court centered on the company's drug candidate efruxifermin ...

Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment.

Other companies with promising MASH programs include Akero Therapeutics, which released positive data on its MASH drug ...

Stocks fell on Monday ahead of a week filled with congressional testimony from Federal Reserve Chairman Jerome Powell and the monthly U.S. jobs report. These stocks made moves Monday: Super Micro ...

The webcast of the fires Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96.

See www.faruqilaw.com. Akero is a clinical stage biopharmaceutical company focused on advancing its lead product candidate efruxifermin ("EFX") to provide a new treatment for patients with ...

See www.faruqilaw.com. Akero is a clinical stage biopharmaceutical company focused on advancing its lead product candidate efruxifermin ("EFX") to provide a new treatment for patients with ...

The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and ...